

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

		1125	vvasningio	on, D.C. 2023 I	\$M
APPLICATION NO.	FILING DATE	FIRST NAMED	INVENTOR		ATTORNEY DOCKET NO.
09/480,38	9 01/11/	00 BOMAN		В	CATX-N
			<u>,</u>		EXAMINER
LEONA L LAUDER			o.	DAVIS,M	
369 PINE STREET			[ART UNIT	PAPER NUMBER
SUITE 610 SAN FRANCISCO CA 94104-3313				1642 DATE MAILED:	10.
					03/30/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

Office Action Summary

Application No 3 89 09/480,398 Applicant(s)

Boman et al

Examiner

Minh-Tam Davis

Group Art Unit 1642



Responsive to communication(s) filed on <u>Dec 19, 2000</u>	<u> </u>
☐ This action is FINAL .	
☐ Since this application is in condition for allowance except in accordance with the practice under <i>Ex parte Quayle</i> , 19	for formal matters, prosecution as to the merits is closed 35 C.D. 11; 453 O.G. 213.
A shortened statutory period for response to this action is set is longer, from the mailing date of this communication. Failur application to become abandoned. (35 U.S.C. § 133). Exten 37 CFR 1.136(a).	e to respond within the period for response will cause the
Disposition of Claims	
	is/are pending in the application.
Of the above, claim(s)	is/are withdrawn from consideration.
Claim(s)	is/are allowed.
☐ Claim(s)	
Claim(s)	· ·
Application Papers	
☐ See the attached Notice of Draftsperson's Patent Draw	ring Review, PTO-948.
☐ The drawing(s) filed on is/are objection	
The proposed drawing correction, filed on	
☐ The specification is objected to by the Examiner.	
☐ The oath or declaration is objected to by the Examiner.	
Priority under 35 U.S.C. § 119	
Acknowledgement is made of a claim for foreign priori	ty under 35 U.S.C. § 119(a)-(d).
☐ All ☐ Some* ☐ None of the CERTIFIED copies	of the priority documents have been
received.	
received in Application No. (Series Code/Serial N	
$\hfill\Box$ received in this national stage application from t	
*Certified copies not received:	
Acknowledgement is made of a claim for domestic price	ority under 35 U.S.C. 3 119(e).
Attachment(s)	
☐ Notice of References Cited, PTO-892	N. (a)
☐ Information Disclosure Statement(s), PTO-1449, Paper	NO(S)
Interview Summary, PTO-413Notice of Draftsperson's Patent Drawing Review, PTO-	-948
☐ Notice of Informal Patent Application, PTO-152	
SEE OFFICE ACTION O	N THE FOLLOWING PAGES

Application/Control Number: 09/480389 Page 2

Art Unit: 1642

DETAILED ACTION

Election/Restriction

1. Restriction to one of the following inventions is required under 35 U.S.C. 121:

Group I. Claims 1-48, drawn to a method for detecting a disease comprising determining whether no wild-type protein expressed by a subject gene is present in a sample, due to mutation in each of the alleles of said subject gene, classified in class 435, subclass 7.1.

Group II. Claims 1-48, drawn to a method for detecting a disease comprising determining whether there is an abnormal low level of wild-type protein expressed by a subject gene in a sample, due to mutation in one of the alleles of said subject gene, classified in class 435, subclass 7.1.

In addition, upon the election of any of groups !-II, further election of the following patentably distinct species of the claimed invention is required:

- 1) Germline mutations or somatic mutations.
- 2) Any one of the biological samples recited in claim 9.
- 3) Any one of the detection methods recited in claim 22.
- 4) Any one of the genes recited in claims 16, 38 and 41.
- 5) Any one of the disease recited in claim 17 and 39.

Upon election of the species body fluids, further election of the following patentably distinct species of the claimed invention is required:

Application/Control Number: 09/480389 Page 3

Art Unit: 1642

Any one of the body fluid recited in claim 10.

2. The inventions are distinct, each from the other because of the following reasons:

The method of groups I is distinct from the method of groups II, because loosing one allele of a gene could result in different diseases and/or disease conditions and disease susceptability, as compared to loosing both alleles of a gene, in which the protein encoded by said gene is complety lost, and because the methods differ at least in method steps, based on different expression properties of a gene.

Further, different types of mutations are patentably distinct because different type of mutation could result in different diseases and/or disease conditions and disease susceptability.

Different genes are patentably distinct because they are structurally distinct.

The species germline mutations and somatic mutations are distinct because they involve different sites of mutation.

The species biological samples and body fluids are distinct because they are different biochemicals with different properties.

The species methods of detection are patentably distinct because they use different method steps, reagents and/or dosages.

Different diseases are patentably distinct because they are

Because these inventions are distinct for the reason given above and have acquired a separate status in the art, and because the searches for the groups are not co-extensive, restriction for examination purposes as indicated is proper.

Application/Control Number: 09/480389 Page 4

Art Unit: 1642

Applicants are required under 35 USC 121 to elect a single disclosed group for prosecution on the merits to which the claims shall be restricted. Applicant is further advised that a response to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 USC 103 of the other invention.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Minh-Tam B. Davis whose telephone number is (703) 305-2008. The examiner can normally be reached on Monday-Friday from 9:30am to 3:30pm, except on Wesnesday.

Application/Control Number: 09/480389

Page 5

Art Unit: 1642

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Tony Caputa, can be reached on (703) 308-3995. The fax phone number for this Group is (703) 308-4227.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0916.

Minh-Tam B. Davis

March 22, 2001